SCHEMBL6626246

SCHEMBL6626246

CSCCNC(=O)NCC(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.54
NPC1 O15118 1/20 0.39
TP53 P04637 1/20 0.39
HPGD P15428 1/20 0.39
NFKB1 P19838 1/20 0.39
MAPK1 P28482 1/20 0.39
RAB9A P51151 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
EGLN1 Q9GZT9 2/20 0.38
PRMT1 Q99873 1/20 0.38
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
PTGS2 P35354 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
RNPEP Q9H4A4 1/20 0.36
ITGB3 P05106 1/20 0.36
ITGB1 P05556 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6626208 0.82 ALDH1A1 (0.52) ALDH1A1NPC1TP53HPGDNFKB1
SCHEMBL2811178 0.79 PRMT1 (0.48) ALDH1A1EGLN1PRMT1LMNAMAPT
SCHEMBL13627871 0.78 ALDH1A1 (0.58) ALDH1A1NPC1TP53HPGDNFKB1
SCHEMBL9856423 0.77 ALDH1A1 (0.56) ALDH1A1NPC1TP53HPGDNFKB1
SCHEMBL17373960 0.76 EGLN1 (0.48) ALDH1A1EGLN1PRMT1LMNAMAPT
SCHEMBL13270863 0.76
SCHEMBL161464 0.76
SCHEMBL29902944 0.75 ALDH1A1 (0.65) ALDH1A1NPC1TP53HPGDNFKB1
SCHEMBL2344568 0.75
SCHEMBL2808458 0.73 PRMT1 (0.67) ALDH1A1MAPK1SMN1; SMN2PRMT1EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1394148-B1 Process for the preparation of alpha-amino acids by hydrolysis of hydantoins at elevated presssure and elevated temperature EVONIK DEGUSSA GMBH (DE) 2016-09-28 EP disclosed
US-9403764-B2 Method of production of a methionine salt EVONIK DEGUSSA GMBH (DE) 2016-08-02 US disclosed
CN-103764240-B Process for preparing methionine salts EVONIK DEGUSSA GMBH (DE) 2016-04-20 CN disclosed
US-20150175535-A1 METHOD OF PRODUCTION OF A METHIONINE SALT EVONIK DEGUSSA GMBH (DE) 2015-06-25 US disclosed
US-9029597-B2 Method for the conversion of methylmercaptopropionaldehyde formed from crude acrolein and crude methyl mercaptan EVONIK DEGUSSA GMBH (DE) 2015-05-12 US disclosed
US-9023284-B2 Method of production of a methionine salt EVONIK DEGUSSA GMBH (DE) 2015-05-05 US disclosed
CN-103764240-A Process for preparing methionine salts EVONIK DEGUSSA GMBH 2014-04-30 CN disclosed
CN-103764239-A Method for the conversion of methyl mercaptopropionaldehyde produced from crude acrolein and crude methyl mercaptan EVONIK DEGUSSA GMBH 2014-04-30 CN disclosed
US-20130245318-A1 METHOD FOR THE CONVERSION OF METHYLMERCAPTOPROPIONALDEHYDE FORMED FROM CRUDE ACROLEIN AND CRUDE METHYL MERCAPTAN EVONIK DEGUSSA GMBH (DE) 2013-09-19 US disclosed
US-20130231501-A1 METHOD OF PRODUCTION OF A METHIONINE SALT EVONIK DEGUSSA GMBH (DE) 2013-09-05 US disclosed
US-6797827-B2 Process for the preparation of alpha-amino acids by hydrolysis of hydantoins at elevated pressure and elevated temperature DEGUSSA AG (DE) 2004-09-28 US disclosed
EP-1394148-A1 Process for the preparation of alpha-amino acids by hydrolysis of hydantoins at elevated presssure and elevated temperature Degussa AG (DE) 2004-03-03 EP disclosed
US-20040039228-A1 Process for the preparation of alpha-amino acids by hydrolysis of hydantoins at elevated pressure and elevated temperature EVONIK DEGUSSA GMBH (DE) 2004-02-26 US disclosed
US-5990349-A Process for the preparation of D,L-methionine or the salt thereof DEGUSSA AKTIENGESELLSCHAFT (DE) 1999-11-23 US disclosed
US-5770769-A Process for the preparation of D,L-methionine or the salt thereof DEGUSSA AKTIENGESELLSCHAFT (DE) 1998-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130231501-A1 METHOD OF PRODUCTION OF A METHIONINE SALT MTR, MSRB3, BHMT2 ALDH1A1 2291/4885NPC1 4093/4885TP53 4479/4885
US-20130245318-A1 METHOD FOR THE CONVERSION OF METHYLMERCAPTOPROPIONALDEHYDE FORMED FROM CRUDE ACROLEIN AND CRUDE METHYL MERCAPTAN MAT2B, MGMT, MMAB ALDH1A1 177/4885NPC1 4504/4885TP53 4353/4885
US-20150175535-A1 METHOD OF PRODUCTION OF A METHIONINE SALT MTR, MSRB3, BHMT2 ALDH1A1 2009/4885NPC1 4219/4885TP53 4518/4885
US-20040039228-A1 Process for the preparation of alpha-amino acids by hydrolysis of hydantoins at elevated pressure and elevated temperature DAO, PEPD, HNMT ALDH1A1 1550/4885NPC1 4047/4885TP53 2046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.